Huntleigh Advisors, Inc. Exagen Inc. Transaction History
Huntleigh Advisors, Inc.
- $586 Billion
- Q3 2025
A detailed history of Huntleigh Advisors, Inc. transactions in Exagen Inc. stock. As of the latest transaction made, Huntleigh Advisors, Inc. holds 93,353 shares of XGN stock, worth $844,844. This represents 0.17% of its overall portfolio holdings.
Number of Shares
93,353
Previous 87,861
6.25%
Holding current value
$844,844
Previous $613 Million
67.29%
% of portfolio
0.17%
Previous 0.12%
Shares
4 transactions
Others Institutions Holding XGN
# of Institutions
64Shares Held
8.96MCall Options Held
25.7KPut Options Held
0-
Rtw Investments, LP New York, NY1.7MShares$15.4 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA734KShares$6.64 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL723KShares$6.55 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA675KShares$6.11 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO552KShares$4.99 Million0.15% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $147M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...